THE EFFECT OF HAART ON HCV REPLICATION AND IMMUNE RESPONSE TO HCV

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。与HIV阴性的人相比，与HIV共同感染的丙型肝炎病毒感染者患肝硬变和肝功能衰竭的风险显著增加。此外，严重的艾滋病毒相关免疫缺陷似乎是晚期肝病的独立预测因素。许多艾滋病毒感染者现在正在接受高效抗逆转录病毒疗法(HAART)的治疗，超过50%的人通过治疗经历了免疫重建。我们将在HAART开始前和12个月后采集混合感染患者的血液并进行肝脏活检。测量丙型肝炎病毒复制和丙型肝炎病毒特异性免疫反应的分析将使我们能够检验有关HAART相关免疫重建对丙型肝炎复制、免疫反应和丙型肝炎病毒肝病的影响的几个假说。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HCV-infected individuals who are co-infected with HIV have a significantly increased risk of cirrhosis and liver failure when compared to those who are HIV-negative. Furthermore, severe HIV-related immunodeficiency appears to be an independent predictor of advanced liver disease. Many HIV-infected individuals are now treated with highly active antiretroviral therapy (HAART), and more than 50% experience immune reconstitution with therapy. We will collect blood and perform liver biopsies in co-infected patients before and 12 months after initiating HAART. Assays measuring HCV replication and the HCV-specific immune response will allow us to test several hypotheses regarding the effect of HAART-related immune reconstitution on hepatitis C replication, immune responses, and HCV liver disease.